Antibodies
14 October 2009
Compugen and Bayer Schering Pharma to Collaborate on Compugen Discovered Oncology Target and Splice Variants9 October 2009
Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist8 October 2009
Lpath’s iSONEP Is Well Tolerated at All Dose Levels in a Phase 1 Trial in Wet-AMD Patients6 October 2009
SurModics Enters Ophthalmic License and Development Agreement with Roche and Genentech5 October 2009
Seattle Genetics Announces Discontinuation of Dacetuzumab Phase IIb Diffuse Large B-Cell Lymphoma Clinical Trial5 October 2009
Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial4 October 2009
Two Phase III Studies of Lucentis Show Early and Sustained Improvement in Vision in Patients with Retinal Vein Occlusion1 October 2009
XOMA Announces Initiation of Its Phase 2 Clinical Program for XOMA 052 in Type 2 Diabetes and Cardiovascular Disease30 September 2009
RoACTEMRA filed in Europe for the Inhibition of Joint Damage and Improvement in Physical Function in Rheumatoid Arthritis30 September 2009
XOMA Presents Results Demonstrating Novel Mechanism of Action for XOMA 052 in Regulating IL-1 Beta Levels30 September 2009
WYETH PHARMACEUTICALS INITIATES PHASE II AND PAYS ABLYNX ANOTHER MILESTONE IN THE TNF-alpha NANOBODY(R) COLLABORATION28 September 2009
Johnson & Johnson and Crucell Announce Strategic Collaboration to Develop Innovative Products, Including Therapies for Influenza Prevention and Treatment28 September 2009
STELARA™ (Ustekinumab) Receives Fda Approval For Treatment Of Moderate To Severe Plaque Psoriasis With Four-Times-A-Year Maintenance Dosing25 September 2009
Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancer24 September 2009
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer24 September 2009
Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects24 September 2009
XOMA to Develop Therapeutic Antibody for H1N1 and H5N1 Influenza Viruses Under $2.2 Million U.S. Government Program Managed by SRI International24 September 2009
Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia23 September 2009
Erbitux Significantly Increases Survival in 1st-Line Metastatic Colorectal Cancer Patients23 September 2009
Initial COIN Study Results Presented at European Oncology CongressNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports